# Alice P. Chen

Source: https://onco.cc/people/alice-chen/  
OnCo record `alice-chen` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer.

## Summary

Alice Chen leads early clinical trials at the National Cancer Institute's Division of Cancer Treatment and Diagnosis and co-led the NCI-MATCH precision medicine trial. She was first author of the 2023 New England Journal of Medicine report of the phase 2 trial in which the PD-L1 antibody atezolizumab produced durable responses in about a quarter of patients with advanced alveolar soft part sarcoma, the basis of the drug's approval for the disease.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: sarcoma; rare-cancers; immunotherapy; trialist
- Role: Medical oncologist, Division of Cancer Treatment and Diagnosis, National Cancer Institute
- Specialisms: Early-phase trials; Rare cancers; Precision oncology trials

## Connected records

- cancers: [Alveolar soft part sarcoma](https://onco.cc/cancers/alveolar-soft-part-sarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- key papers: [Atezolizumab for advanced alveolar soft part sarcoma](https://onco.cc/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/alice-chen.json